Sestrin-2 Levels and Insulin Resistance | NCT06779721

Studies
Sestrin-2 Levels and Insulin Resistance

NCT06779721

Sponsor

Kayseri City Hospital

Status

Completed

Last Update Posted

Jan 17, 2025Actual

Enrollment

89Actual

Phase

Not provided

Conditions

Obese Adolescents

Interventions

Sestrin-2

Countries

Turkey (Türkiye)

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2025

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jun 20, 2021Actual

Primary Completion Date

Jan 20, 2022Actual

Completion Date

Feb 15, 2022Actual

First Submitted Date

Jan 13, 2025

First Submission Date that Met QC Criteria

Jan 13, 2025

First Posted Date

Jan 16, 2025Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 16, 2025

Last Update Posted Date

Jan 17, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

FDAAA801 Violation

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

89Actual

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Sestrin-2	Other	Sestrin-2 levels were studied in three different groups

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Evaluation of sestrin-2 levels in obese and healthy participants		From enrollment to the end of 6 months

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2

Exclusion Criteria:

Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

10 Years

Maximum Age

18 Years

Standard Ages

ChildAdult

Study Population

Obese and healthy adolescents who admitted to Kayseri City Hospital

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Kayseri City Hospital		Kayseri		38125	Turkey (Türkiye)

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
40621934	Derived	Soylu Ustkoyuncu P, Kocer D. Sestrin-2 levels and insulin resistance in childhood obesity. J Investig Med. 2026 Apr;74(3):254-259. doi: 10.1177/10815589251359311. Epub 2025 Jul 7.

ID	Term
D063766	Pediatric Obesity
D007333	Insulin Resistance

ID	Term
D009765	Obesity
D050177	Overweight
D044343	Overnutrition
D009748	Nutrition Disorders